Federal funding for overdose prevention and harm reduction services expands.
H.R. 11035 — Closing the Substance Use Care Gap Act of 2026 · Filed by Rick Larsen (D-WA) · Introduced Nov 13, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes $30 million per year (2027–2031) in federal grants to states, local governments, tribes, nonprofits, and health organizations to fund community-based harm reduction programs for people who use substances. Eligible programs include syringe services, overdose prevention and reversal medication distribution, and connecting people to treatment and recovery services. The bill requires grantees to establish referral pathways to evidence-based treatment.
Why we flagged it
The bill's sole operative mechanism is the creation of a new federal grant program to fund community-based harm reduction services. It is a straightforward public health appropriation with no riders, carve-outs, or private beneficiaries.
What the text implies
- Requires grantees to establish referral pathways to treatment, potentially increasing demand for substance use disorder treatment capacity—states may need to expand treatment infrastructure to meet referrals.
- Syringe services programs funded under this bill may face local political opposition in some jurisdictions despite federal authorization, creating implementation friction.
- The 2% cap on federal administrative expenses may constrain HHS's ability to monitor program quality and outcomes across diverse grantees.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill expands access to evidence-based harm reduction services—overdose reversal medication, disease prevention, and treatment referral—for a vulnerable population with high mortality and morbidity. Harm reduction is a public health standard supported by CDC and medical evidence; the bill does not restrict any existing rights or protections and funds services that reduce preventable deaths and disease.
Who stands to gain
- community-based harm reduction programs
- syringe services programs
- opioid treatment programs
- federally qualified health centers
- nonprofit health organizations
- tribal health organizations
Named in the bill
Department of Health and Human Services, Assistant Secretary for Mental Health and Substance Use, Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Administration, Tribal Training and Technical Assistance Center, state and local governments, tribal governments, federally qualified health centers, opioid treatment programs, urban Indian organizations
Where it stands
- Nov 13, 2026 — Introduced · Congress.gov: “Introduced in House”
- Nov 13, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (6,036 characters) on Nov 14, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-11-22.
“Federal funding for overdose prevention and harm reduction services expands.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr11035 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.